| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 15002144251 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:MAGLi 432 CAS:2361575-20-2 Package:1removed
|
| Company Name: |
https://hanhongsci.com/
|
| Tel: |
021-54306202 18917919676 |
| Email: |
info@hanhongsci.com |
| Products Intro: |
Product Name:MAGLi 432 CAS:2361575-20-2 Purity:98% Package:5mg;25mg;100mg;1g;5g
|
Methanone, (2-bromo-3-methoxyphenyl)[(7R,9aR)-7-(4-chlorophenyl)octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]- manufacturers
- MAGLi 432
-
- $3520.00
-
2026-05-11
- CAS:2361575-20-2
- Purity:
- Supply Ability: 10g
|
| | Methanone, (2-bromo-3-methoxyphenyl)[(7R,9aR)-7-(4-chlorophenyl)octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]- Basic information |
| Product Name: | Methanone, (2-bromo-3-methoxyphenyl)[(7R,9aR)-7-(4-chlorophenyl)octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]- | | Synonyms: | Methanone, (2-bromo-3-methoxyphenyl)[(7R,9aR)-7-(4-chlorophenyl)octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-;[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(2-bromo-3-methoxyphenyl)methanone | | CAS: | 2361575-20-2 | | MF: | C22H24BrClN2O2 | | MW: | 463.8 | | EINECS: | | | Product Categories: | | | Mol File: | 2361575-20-2.mol | ![Methanone, (2-bromo-3-methoxyphenyl)[(7R,9aR)-7-(4-chlorophenyl)octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]- Structure](CAS/20210305/GIF/2361575-20-2.gif) |
| | Methanone, (2-bromo-3-methoxyphenyl)[(7R,9aR)-7-(4-chlorophenyl)octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]- Chemical Properties |
| Boiling point | 589.6±50.0 °C(Predicted) | | density | 1.46±0.1 g/cm3(Predicted) | | pka | 8.43±0.40(Predicted) |
| | Methanone, (2-bromo-3-methoxyphenyl)[(7R,9aR)-7-(4-chlorophenyl)octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]- Usage And Synthesis |
| Uses | MAGLi 432 is a non-covalent, potent, highly selective, and reversible MAGL inhibitor. MAGLi 432 binds with high affinity to the MAGL active site, with IC50 values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme). MAGLi 432 can be used in the research of chronic inflammation, blood–brain barrier dysfunction, neurological disorders such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease[1]. | | in vivo | MAGLi 432 (intraperitoneal injection, 1 mg/kg for 3 consecutive days) inhibits MAGL in the brain and reduces arachidonic acid and PGE2 levels in LPS-induced neuroinflammation, without reducing BBB permeability and inflammatory cytokine expression in the cortex[1]. | Animal Model: | Male CD-1 mice model of LPS-induced neuroinflammation[1] | | Dosage: | 1 mg/kg for 3 consecutive days | | Administration: | Intraperitoneal injection | | Result: | Accumulated ~10-fold more 2-AG than vehicle controls, reducted LPS-induced PGE2.
Increased LCN2 and TNF expression compared to the LPS treatment.
|
| | References | [1] Alicia Kemble, et al. A potent and selective inhibitor for the modulation of MAGL activity in the neurovasculature. bioRxiv 2022.05.04.490688. |
| | Methanone, (2-bromo-3-methoxyphenyl)[(7R,9aR)-7-(4-chlorophenyl)octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]- Preparation Products And Raw materials |
|